Abstract
Gestational diabetes mellitus (GDM) and pre-gestational diabetes are known to pose risks to the mother and developing fetus, often related to abnormal fetal growth. One potential mediator of maternal effects on fetal growth is Placental Growth Hormone (PGH). PGH is produced by the syncytiotrophoblast and found predominantly in the maternal circulation. It progressively replaces pituitary growth hormone (hGH) in the human maternal circulation from midgestation onwards, peaking towards term. PGH appears to be an important potential regulator of maternal insulin resistance in human pregnancy and may influence fetal growth both by modifying substrate availability and through paracrine actions in the placental bed. The details of PGH regulation remain relatively poorly understood, but current evidence does suggest a central role in growth restricted pregnancies. There is currently less evidence of a pathophysiologic role in production of the macrosomic fetal phenotype commonly seen in response to hyperglycaemia, although our recent in vitro studies do raise the possibility of feto-placental feedback as a mechanism of growth modulation.
Keywords: Placental growth hormone, Insulin-like Growth Factor-1, Diabetes, Pregnancy, Fetal growth, Insulin resistance
Current Diabetes Reviews
Title: Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy
Volume: 5 Issue: 3
Author(s): H. D. McIntyre, W. Zeck and A. Russell
Affiliation:
Keywords: Placental growth hormone, Insulin-like Growth Factor-1, Diabetes, Pregnancy, Fetal growth, Insulin resistance
Abstract: Gestational diabetes mellitus (GDM) and pre-gestational diabetes are known to pose risks to the mother and developing fetus, often related to abnormal fetal growth. One potential mediator of maternal effects on fetal growth is Placental Growth Hormone (PGH). PGH is produced by the syncytiotrophoblast and found predominantly in the maternal circulation. It progressively replaces pituitary growth hormone (hGH) in the human maternal circulation from midgestation onwards, peaking towards term. PGH appears to be an important potential regulator of maternal insulin resistance in human pregnancy and may influence fetal growth both by modifying substrate availability and through paracrine actions in the placental bed. The details of PGH regulation remain relatively poorly understood, but current evidence does suggest a central role in growth restricted pregnancies. There is currently less evidence of a pathophysiologic role in production of the macrosomic fetal phenotype commonly seen in response to hyperglycaemia, although our recent in vitro studies do raise the possibility of feto-placental feedback as a mechanism of growth modulation.
Export Options
About this article
Cite this article as:
McIntyre D. H., Zeck W. and Russell A., Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy, Current Diabetes Reviews 2009; 5 (3) . https://dx.doi.org/10.2174/157339909788920947
DOI https://dx.doi.org/10.2174/157339909788920947 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Human Placental Villous Tissue Explants to Study ABC Transporter Mediated Efflux of 2,4-Dinitrophenyl-S-Glutathione
Current Pharmaceutical Biotechnology Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Surfactant Protein D in Chronic Obstructive Pulmonary Disease (COPD)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Dietary Polyphenols in the Intervention of Gestational Diabetes
Current Traditional Medicine Pharmacogenetics in Type 2 Diabetes: Polymorphisms in Candidate Genes Affecting Responses to Antidiabetic Oral Treatment
Current Pharmacogenomics Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Can Life Before Birth Affect Health Ever After?
Current Women`s Health Reviews Erythropoietin and Oxidative Stress
Current Neurovascular Research Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Plasticity of Neuroendocrine-Immune Interactions During Ontogeny: Role of Perinatal Programming in Pathogenesis of Inflammation and Stress- Related Diseases in Adults
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design Pulmonary Embolism and Pregnancy
Current Women`s Health Reviews Editorial (Thematic Issue: “Pregnancy in Women with Metabolic Syndrome”)
Current Pharmaceutical Biotechnology MicroRNAs in Diabetic β Cell Dysfunction and their Role as Biomarkers
Current Signal Transduction Therapy Regeneration of Pancreatic β-Cells in vivo as a Potential Therapeutic Approach for Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Annexins in the Central Nervous System: Are they Neuroprotective or Proapoptotic Agents?
Medicinal Chemistry Reviews - Online (Discontinued) DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design